In particular, BCR-stimulated VLA-4 activation in CLL cells derived from patients that were 90 days on ibrutinib was comparable to the activation observed in untreated patients; this leads to the question of whether BTK can be bypassed by other kinases during antigen-stimulated inside-out VLA-4 activation. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.